Alkermes ALKS Stock
Alkermes Price Chart
Alkermes ALKS Financial and Trading Overview
| Alkermes stock price | 27.84 USD |
| Previous Close | 31.76 USD |
| Open | 31.78 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 31.65 - 32.11 USD |
| 52 Week Range | 21.75 - 32.28 USD |
| Volume | 944.69K USD |
| Avg. Volume | 1.28M USD |
| Market Cap | 5.3B USD |
| Beta (5Y Monthly) | 0.605281 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 2.2 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.22 USD |
ALKS Valuation Measures
| Enterprise Value | 5.07B USD |
| Trailing P/E | N/A |
| Forward P/E | 17.448088 |
| PEG Ratio (5 yr expected) | 1.52 |
| Price/Sales (ttm) | 4.732361 |
| Price/Book (mrq) | 5.272457 |
| Enterprise Value/Revenue | 4.523 |
| Enterprise Value/EBITDA | -59.09 |
Trading Information
Alkermes Stock Price History
| Beta (5Y Monthly) | 0.605281 |
| 52-Week Change | 13.91% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 32.28 USD |
| 52 Week Low | 21.75 USD |
| 50-Day Moving Average | 29.88 USD |
| 200-Day Moving Average | 26.43 USD |
ALKS Share Statistics
| Avg. Volume (3 month) | 1.28M USD |
| Avg. Daily Volume (10-Days) | 1.32M USD |
| Shares Outstanding | 166.12M |
| Float | 149.71M |
| Short Ratio | 6.43 |
| % Held by Insiders | 1.75% |
| % Held by Institutions | 103.16% |
| Shares Short | 7.13M |
| Short % of Float | 4.90% |
| Short % of Shares Outstanding | 4.29% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -14.64% |
| Operating Margin (ttm) | -14.55% |
| Gross Margin | 80.47% |
| EBITDA Margin | -7.65% |
Management Effectiveness
| Return on Assets (ttm) | -5.22% |
| Return on Equity (ttm) | -15.78% |
Income Statement
| Revenue (ttm) | 1.12B USD |
| Revenue Per Share (ttm) | 6.83 USD |
| Quarterly Revenue Growth (yoy) | 3.20% |
| Gross Profit (ttm) | 893.69M USD |
| EBITDA | -85795000 USD |
| Net Income Avi to Common (ttm) | -164208992 USD |
| Diluted EPS (ttm) | -1.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 600.46M USD |
| Total Cash Per Share (mrq) | 3.62 USD |
| Total Debt (mrq) | 394.05M USD |
| Total Debt/Equity (mrq) | 39.19 USD |
| Current Ratio (mrq) | 2.252 |
| Book Value Per Share (mrq) | 6.056 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -21936000 USD |
| Levered Free Cash Flow (ttm) | 34.39M USD |
Profile of Alkermes
| Country | United States |
| State | N/A |
| City | Dublin |
| Address | Connaught House |
| ZIP | D04 C5Y6 |
| Phone | 353 1 772 8000 |
| Website | https://www.alkermes.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 2280 |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Q&A For Alkermes Stock
What is a current ALKS stock price?
Alkermes ALKS stock price today per share is 27.84 USD.
How to purchase Alkermes stock?
You can buy ALKS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alkermes?
The stock symbol or ticker of Alkermes is ALKS.
Which industry does the Alkermes company belong to?
The Alkermes industry is Drug Manufacturers-Specialty & Generic.
How many shares does Alkermes have in circulation?
The max supply of Alkermes shares is 164.84M.
What is Alkermes Price to Earnings Ratio (PE Ratio)?
Alkermes PE Ratio is 12.65454500 now.
What was Alkermes earnings per share over the trailing 12 months (TTM)?
Alkermes EPS is 2.2 USD over the trailing 12 months.
Which sector does the Alkermes company belong to?
The Alkermes sector is Healthcare.
Alkermes ALKS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| Dow Jones U.S. Biotechnology In DJUSBT | 2516.6 USD — |
+0.36
|
143.99M USD — | 2467.66 USD — | 2525.99 USD — | — - | 143.99M USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
| NYSE ARCA PHARMACEUTICAL INDEX DRG | 944.41 USD — |
+1.23
|
— — | — — | — — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4470.08 USD — |
-1.41
|
— — | 4446.23 USD — | 4506.67 USD — | — - | — — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1337.85 USD — |
+0.58
|
— — | 1310.31 USD — | 1340.24 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2752.75 USD — |
+0.32
|
— — | 2724.48 USD — | 2752.94 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 21278.67 USD — |
+1.26
|
— — | 20945.45 USD — | 21305.05 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8504.39 USD — |
+1.34
|
— — | 8367.19 USD — | 8515.13 USD — | — - | — — |
- {{ link.label }} {{link}}